Technology | Lung Cancer | August 28, 2017

20/20 GeneSystems Launches AI-Based Lung Cancer Detection Technology in China

Platform represents first machine learning approach available to hospitals to aid in evaluating ambiguous pulmonary nodules

20/20 GeneSystems Launches AI-Based Lung Cancer Detection Technology in China

August 28, 2017 — 20/20 GeneSystems Inc. recently released in China what is believed to be the world’s first machine learning algorithm commercialized for use in conjunction with blood tests to aid in the early detection of lung cancer. The cloud-accessible software, marketed in China by MyBioMed Ltd., is expected to be utilized over the next six months by at least 20 hospitals in five or more cities to help in distinguishing between benign versus malignant pulmonary nodules following computed tomography (CT) imaging.

The algorithm, built and validated with data from over 1,000 patients tested at the Tianjin Cancer Institute combines the values of biomarker — tumor-associated proteins in the blood — and individual patient characteristics such as their age, smoking status and nodule size. It could potentially increase the number of cancers detected by more than 50 percent over current methods. Artificial neural networks are incorporated to permit continuous improvements as more data is acquired over time.

Lung cancer is a significant burden in China as more than half of adult men in that country are current or former smokers and heavy air pollution further contributes to the disease. "Lung cancer in China has a very high disease incidence and the current solution is to do early screening which often leads to good outcomes at a low cost,” said Yilong Wu, M.D. chair of the Chinese Society of Clinical Oncology and himself a chest surgeon and lung cancer expert. “Low-dose CT (LDCT) screening has been recognized worldwide as an approach to reduce lung cancer mortality but these scans uncover many nodules that turn out to be benign, and unneeded biopsies and surgery can be dangerous to many patients,” he added. “I am very optimistic about the approach introduced by 20/20 and MBM of adding bioinformatics and artificial intelligence methods to improve the sensitivity and specificity of detection and look forward to seeing continued expansion of their data sets and confirmatory studies."

20/20’s cloud-based lung nodule assessment software is the company’s first product marketed using a software-as-a-service (SaaS) revenue model, according to 20/20 CEO Jonathan Cohen.

For more information: www.2020gene.com

Related Content

John Carrino, M.D., M.Ph., presents “Challenges and Opportunities for Radiology to Prove Value in Alternative Payment Models” at AHRA 2019

John Carrino, M.D., M.Ph., presents “Challenges and Opportunities for Radiology to Prove Value in Alternative Payment Models” at AHRA 2019. Photo by Greg Freiherr

Feature | Radiology Business | July 22, 2019 | By Greg Freiherr
Efforts to reform healthcare are booming, b
IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Videos | Computed Tomography (CT) | July 19, 2019
Quynh Truong, M.D., MPH, associate professor of radio
Low Doses of Radiation Promote Cancer-capable Cells
News | Radiation Dose Management | July 18, 2019
Low doses of radiation equivalent to three computed tomography (CT) scans, which are considered safe, give cancer-...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
New Lung Ambition Alliance Aims to Double Five-year Lung Cancer Survival by 2025
News | Lung Cancer | July 17, 2019
The International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (...
Example of an intentionally truncated CT image

Figure 1: Example of an intentionally truncated CT image. The truncation percentage was calculated as the ratio of the patient border touching the field of view to the total patient border (red/(read+blue)). Image courtesy of Qaelum.

Feature | Radiation Dose Management | July 15, 2019 | Niki Fitousi, Ph.D., and An Dedulle
One of the main benefits of a radiation dose management system is the possibility to automatically generate alerts when...
Graphic courtesy Pixabay

Graphic courtesy Pixabay

Feature | Artificial Intelligence | July 15, 2019 | By Greg Freiherr
Siemens has long focused on automation as a way to make diagnostic equipment faster and more efficient.